United States

People: Rocket Pharmaceuticals Inc (RCKT.OQ)

RCKT.OQ on NASDAQ Stock Exchange Global Market

12:47pm EST
Change (% chg)

$0.07 (+0.44%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Baumgartner, Rudolf 

Dr. Rudolf A. Baumgartner, M.D. is Executive Vice President, Chief Medical Officer of the Company. Dr. Baumgartner, our Executive Vice President and Chief Medical Officer, which we amended on December 23, 2008, October 9, 2009 and September 12, 2017. In 2017, Dr. Baumgartner received a base salary of $404,872. In 2017, Dr. Baumgartner was eligible for an annual performance bonus with a target amount of 35% of his base salary. For 2017, the Compensation Committee awarded Dr. Baumgartner a retention bonus of $141,785, representing 35% of his 2017 base salary, in exchange for his continued active employment in a full-time capacity through the effective time of the Reverse Merger. Dr. Baumgartner was eligible to participate in our employee benefit plans in effect from time to time, subject to the terms of those plans. Subject to the execution and effectiveness of a separation agreement, including, among other things, a general release of claims, Dr. Baumgartner would have been eligible to receive the following payments and benefits in the event that his employment had been terminated by us without cause or by him for good reason as of the last day of the fiscal year: base salary continuation for twelve months; a monthly cash payment equal to the monthly employer contribution to provide him health and dental insurance coverage if he had remained employed by us until 12 months following the date of termination; and accelerated vesting of all outstanding equity awards. In connection with the consummation of the Reverse Merger and his termination of employment, Dr. Baumgartner became entitled to the foregoing severance benefits and all of his outstanding equity awards were accelerated. The receipt of the severance payments and benefits set forth above are conditioned upon Dr. Baumgartner not violating the terms of a restrictive covenant agreement between Dr. Baumgartner and Inotek.

Basic Compensation

Total Annual Compensation, USD 546,657
Restricted Stock Awards, USD 266,875
Long-Term Incentive Plans, USD --
All Other, USD 14,016
Fiscal Year Total, USD 827,548

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --